Endoscopic ultrasound-guided injectable therapy for pancreatic cancer: A systematic review.
Chemotherapy
Endoscopic ultrasound-guided fine-needle injection
Immunotherapy
Local injectable therapy
Oncolytic viral therapy
Pancreatic ductal adenocarcinoma
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
received:
10
12
2021
revised:
18
01
2022
accepted:
22
04
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
12
7
2022
Statut:
ppublish
Résumé
Given the low survival rate in pancreatic cancer, new therapeutic techniques have been explored, especially for unresectable or borderline resectable disease. Endoscopic ultrasound (EUS) provides real-time imaging and minimally invasive access for local and targeted injection of anti-tumor agents directly into the pancreatic tumor. Limited studies have been reported using this technique for the treatment of pancreatic ductal adenocarcinoma (PDAC). To evaluate the progress made with EUS-guided injectable therapies in the treatment of PDAC. All original articles published in English until July 15, 2021, were retrieved A total of thirteen articles (503 patients) were found eligible for inclusion. The EUS-injectable therapies used were heterogeneous among the studies consisting of immunotherapy ( EUS-guided injectable therapies, including immunotherapy, chemotherapy, and viral or other biological therapies have shown minimal adverse events and potential efficacy in the treatment of PDAC. Comparative studies, including controlled trials, are required to confirm these results in order to offer novel EUS-based treatment options for patients with PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
Given the low survival rate in pancreatic cancer, new therapeutic techniques have been explored, especially for unresectable or borderline resectable disease. Endoscopic ultrasound (EUS) provides real-time imaging and minimally invasive access for local and targeted injection of anti-tumor agents directly into the pancreatic tumor. Limited studies have been reported using this technique for the treatment of pancreatic ductal adenocarcinoma (PDAC).
AIM
OBJECTIVE
To evaluate the progress made with EUS-guided injectable therapies in the treatment of PDAC.
METHODS
METHODS
All original articles published in English until July 15, 2021, were retrieved
RESULTS
RESULTS
A total of thirteen articles (503 patients) were found eligible for inclusion. The EUS-injectable therapies used were heterogeneous among the studies consisting of immunotherapy (
CONCLUSION
CONCLUSIONS
EUS-guided injectable therapies, including immunotherapy, chemotherapy, and viral or other biological therapies have shown minimal adverse events and potential efficacy in the treatment of PDAC. Comparative studies, including controlled trials, are required to confirm these results in order to offer novel EUS-based treatment options for patients with PDAC.
Identifiants
pubmed: 35800184
doi: 10.3748/wjg.v28.i21.2383
pmc: PMC9185216
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2383-2395Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There are no conflicts of interest to report.
Références
Clin Gastroenterol Hepatol. 2021 May;19(5):876-884
pubmed: 32147593
Cancer Res. 1999 Jul 15;59(14):3329-32
pubmed: 10416588
Cell Res. 2017 Jan;27(1):74-95
pubmed: 28025976
J Gastroenterol Hepatol. 2009 Apr;24(4):509-19
pubmed: 19220671
Ann Surg Oncol. 1998 Dec;5(8):681-8
pubmed: 9869513
Cancer Res. 2003 Jul 15;63(14):4112-8
pubmed: 12874015
Mol Ther. 2007 May;15(5):1016-23
pubmed: 17375076
Cancer Gene Ther. 2012 Jun;19(6):374-81
pubmed: 22498722
Pathol Oncol Res. 2012 Oct;18(4):771-81
pubmed: 22714538
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
J Am Coll Surg. 1999 Jul;189(1):1-7
pubmed: 10401733
Cancer Res. 2004 Jul 15;64(14):4973-9
pubmed: 15256471
Clin Endosc. 2020 Sep;53(5):535-540
pubmed: 33027583
Gene Ther. 2001 Feb;8(4):308-15
pubmed: 11313805
Oncoimmunology. 2013 Jun 1;2(6):e24612
pubmed: 23894720
Semin Oncol. 2007 Aug;34(4):311-20
pubmed: 17674959
J Crohns Colitis. 2017 Feb;11(2):221-228
pubmed: 27484097
Curr Gastroenterol Rep. 2019 Apr 23;21(5):19
pubmed: 31016391
PLoS One. 2015 Dec 07;10(12):e0142981
pubmed: 26642349
J Virol. 2002 Jul;76(13):6718-28
pubmed: 12050385
Onco Targets Ther. 2020 Dec 10;13:12705-12720
pubmed: 33335406
Endoscopy. 2007 Jun;39(6):530-4
pubmed: 17554649
J Clin Oncol. 2004 Apr 15;22(8):1389-97
pubmed: 15084613
J Clin Oncol. 2013 Mar 1;31(7):886-94
pubmed: 23341531
J Oncol. 2010;2010:178174
pubmed: 21052499
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer Lett. 2019 Mar 31;445:57-64
pubmed: 30641107
Oncolytic Virother. 2014 Feb 17;3:35-46
pubmed: 27512661
Gastrointest Endosc Clin N Am. 2005 Jan;15(1):169-77, x
pubmed: 15555959
Cancer Treat Rev. 2019 Jul;77:1-10
pubmed: 31163334
Gastrointest Endosc. 2018 Apr;87(4):1126-1131
pubmed: 29122598
Cancer. 2000 Mar 15;88(6):1325-35
pubmed: 10717613
Clin Cancer Res. 2003 Feb;9(2):555-61
pubmed: 12576418
Gastrointest Endosc. 2020 Nov;92(5):1044-1052.e1
pubmed: 32084409
Cancer J Sci Am. 1995 Sep-Oct;1(3):204-9
pubmed: 9166477
Pancreas. 2007 Aug;35(2):189-90
pubmed: 17632329
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Mol Clin Oncol. 2013 Mar;1(2):231-234
pubmed: 24649152
J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):465-75
pubmed: 21983893
Gut. 2011 Jun;60(6):861-8
pubmed: 20966025
Pancreas. 2009 Apr;38(3):e69-74
pubmed: 19276867
Gastrointest Endosc. 2017 Jul;86(1):161-169
pubmed: 27889543
Oncotarget. 2017 Dec 5;9(2):2838-2847
pubmed: 29416816
Am J Gastroenterol. 2008 Jan;103(1):98-103
pubmed: 17970834
Endosc Int Open. 2019 Aug;7(8):E1008-E1017
pubmed: 31404394
Gastrointest Endosc. 2012 Feb;75(2):332-8
pubmed: 22248601
BMC Cancer. 2018 May 25;18(1):596
pubmed: 29801474